Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehrdad Rakaee

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Nature Communications|August 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinomaAmin H Nassar, Chul Kim, Tolulope Adeyelu, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Nature Communications|August 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinomaAmin H Nassar, Chul Kim, Tolulope Adeyelu, et al.
Pageof 5